Key result
Higher burden of medical comorbidity and greater number of affected organ systems significantly predicted poorer clinical response and lower remission rates during 8 weeks of fluoxetine treatment.
Why the study?
Does medical comorbidity impact the response to acute fluoxetine treatment in outpatients with major depressive disorder?
Population
384 outpatients meeting DSM-III-R criteria for major depressive disorder
Design
Cohort, open-label
Follow-up
8 weeks
Authors
Loading...
Medical comorbidity may reduce fluoxetine response in MDD; hypothesis-generating and should not yet change practice.
Cohort (n=384)
Open-label
Does medical comorbidity impact the response to acute fluoxetine treatment in outpatients with major depressive disorder?
Higher medical comorbidity burden negatively predicts clinical response and remission during acute fluoxetine treatment for major depressive disorder.
Iosifescu et al. (2003) conducted a cohort in Major depressive disorder (n=384). Medical comorbidity was evaluated on Response to treatment (≥50% reduction in Hamilton Rating Scale for Depression score) and clinical remission (score ≤7). Higher burden of medical comorbidity and greater number of affected organ systems significantly predicted poorer clinical response and lower remission rates during 8 weeks of fluoxetine treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: